Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy and GSK agree to settle on US valacyclovir patent

Ranbaxy reaches an agreement with GSK to dismiss its US litigation with regard to anti-infective Valtrex

India-headquartered Ranbaxy has reached an agreement with GlaxoSmithKline (GSK) to dismiss its US litigation with regard to anti-infective, Valtrex (valacyclovir).

The US lawsuit was related to GSK's US Patent 4,957,924, covering valacyclovir and its use in the treatment of herpes simplex infection.

Per the agreement, Ranbaxy will enter the US market in late 2009 as the first generic version of valacyclovir and company will benefit from a 180-day exclusivity arrangement. Ranbaxy received a final approval from the FDA to market and manufacture valacyclovir tablets in February 2007.

Ranbaxy has also obtained a license to GSK's US Patents 5,879,706 and 6,107,302, listed in the Orange Book for valacyclovir. The total annual market sales of Valtrex were approximately USD 1.3bn, according to IMS MIDAS data.

Ranbaxy says it has a First-to File (FTF) status on around 20 Para IV ANDA filings, which at current ethical prices could offer a potential market size of USD 26bn.

30th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics